AI-generated from publicly available materials.Eli Lilly has strengthened its global partnership with Veeva Systems by adopting the Vault CRM System, a move aimed at enhancing the efficiency of its commercial operations and expanding patient access to innovative medicines. This collaboration underscores the pharmaceutical industry's increasing reliance on AI-driven solutions.
The transition to Vault CRM marks a significant upgrade from Veeva's previous CRM platform, which was based on Salesforce. This shift is part of Veeva's strategy to promote an "agentic commercial" model, which utilizes AI to optimize interactions between life sciences companies and healthcare providers. Peter Gassner, CEO of Veeva Systems, emphasized the long-standing relationship between the two companies, framing this transition as a natural evolution rather than a new partnership.
The integration of AI into the Vault CRM system includes features like the Agentic Call Report, which automates the generation of commercial insights from field interactions. This innovation aims to alleviate the administrative burden on sales teams, allowing them to focus more on engaging with healthcare providers rather than on manual reporting tasks.
Eli Lilly's collaboration with Veeva is part of a broader strategy to enhance its technological capabilities. The company is also partnering with NVIDIA to develop a powerful supercomputer for drug discovery and has made significant investments in AI-driven initiatives, including a partnership with Insilico Medicine and a stake in Abridge. These efforts illustrate Lilly's commitment to embedding AI across its operations, from research and development to commercial functions.